Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile LaunchInvestors Business Daily • 02/28/24
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating OverviewBusiness Wire • 02/27/24
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024Business Wire • 02/13/24
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi FamiliesSeeking Alpha • 01/23/24
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024Business Wire • 12/21/23
Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)Business Wire • 12/14/23
Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest DrugInvestors Business Daily • 12/13/23
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent LitigationBusiness Wire • 12/13/23
Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi SyndromeBusiness Wire • 11/30/23
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)Zacks Investment Research • 11/30/23
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer's Disease PsychosisBusiness Wire • 11/27/23
5 Biotech Stocks Likely to Thrive as Industry Prospects Look BrightZacks Investment Research • 11/22/23
Acadia Pharmaceuticals Announces Change in Research and Development LeadershipBusiness Wire • 11/21/23
Wall Street Analysts Predict a 37.65% Upside in Acadia (ACAD): Here's What You Should KnowZacks Investment Research • 11/20/23